Kad Anti / Shutterstock.com
Two decisions from the European Patent Office offer important guidance for healthcare inventions that use computers, says Rosie McDowell of EIP.
As patent attorneys practising in the healthcare sector, we are encountering more and more inventions which straddle the life and computer science fields. AI and smart technologies are now a central feature in many medical technologies.
In claims incorporating the use of computer technology, a key consideration is that the invention must have “technical character”.
The case law in this area typically concerns technologies that are far removed from the inventions arising in the healthcare and pharmaceutical sectors.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
European patent office, EPO, Boards of Appeal, T-1234/17, T 0752/19, second medical use, data, computer, software, pharma